Selexis, Xencor in Pact for Bispecific Antibodies
By
Selexis SA, a Geneva, Switzerland-based provider of mammalian cell-line generation technology, has signed four commercial license agreements (CLAs) to extend its pact with Xencor, a Monrovia, California-based clinical-stage biopharmaceutical company…
GlaxoSmithKline Voluntarily Recalls Three Lots of Respiratory Inhalers in UK
By
The Medicines and Healthcare products Regulatory Agency (MHRA), the UK’s regulatory authority, has issued a patient-level drug alert recalling three specific affected lots of respiratory inhalers manufactured by GlaxoSmithKline (GSK).…
Fresenius’ Closing of $4.3-Billion Acquisition of Akorn Faces Possible Issues with Data-Integrity Probe
By
Fresenius Kabi, a specialty and generic pharmaceuticals company, may face issues with its pending $4.3-billion acquisition of Akorn, a Lake Forest, Illinois-headquartered specialty generic pharmaceutical company, following Akorn’s alleged breaches…